SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SoFi Technologies, Inc. is a financial service platform, which engages in the provision of student loan refinancing options to the private student loan market. It operates through the following segments: Lending, Technology Platform, and Financial Services. The Lending segment offers personal loans, student loans, home loan products, and related servicing activities. The Technology Platform segment focuses on technology products and solutions revenue. The Financial Services segment includes the SoFi Money product, SoFi Invest product, SoFi Credit Card product, SoFi Relay personal finance management product, and other financial services such as lead generation and content for other financial services institutions. The company was founded in 2011 and is headquartered in San Francisco, CA.

SoFi Technologies Inc

SoFi is trending amid discussions around its growth potential, analyst ratings, and overall market sentiment. Community members are actively debating its valuation, with some citing strong revenue growth and potential benefits from future rate cuts, while others express concerns about dilution and overvaluation. The stock's movements are also being tied to broader market trends and upcoming economic data releases.

Galaxy Digital, Inc. engages in digital assets and data center infrastructure, delivering solutions that accelerate progress in finance and artificial intelligence. It operates through the following segments: Digital Assets and Data Centers. The digital assets segment offers institutional access to trading, advisory, asset management, staking, self-custody, and tokenization technology. The Data Centers segment competes with a range of infrastructure providers that are building or repurposing facilities to support the rapidly growing demand for AI and compute-intensive workloads. The company was founded by Michael Novogratz in 2018 and is headquartered in New York, NY.

Galaxy Digital Inc. - Ordinary Shares - Class A

Galaxy Digital is trending amid discussions around its correlation to crypto markets and AI data center prospects, with some traders expressing frustration over its price action and potential manipulation. Community members are debating its valuation and future performance, particularly in relation to upcoming earnings and Helios updates. Bearish sentiment is emerging with some traders targeting lower price points.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron is trending due to positive sentiment around its role in AI and potential benefits from new export regulations impacting competitors. Community members are discussing Micron's commitment to AI education and the potential for increased demand for its HBM and DRAM products. Bullish sentiment is fueled by expectations of strong earnings and a possible breakout, with some anticipating significant gains in the coming months.

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

Robinhood's stock is trending amid speculation about potential S&P 500 inclusion and excitement surrounding the launch of NFL and college football prediction markets on the platform. Community discussions revolve around whether the stock will be added to the S&P 500, with some anticipating a surge if it happens, while others focus on the potential revenue boost from the new sports betting feature. The stock's behavior relative to the broader market and key technical levels are also being closely monitored.

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Vienna, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MicroStrategy ($MSTR) is trending as investors anticipate a potential S&P 500 inclusion announcement, which could trigger significant passive inflows. Community discussions revolve around the stock's correlation to Bitcoin, concerns about dilution, and whether it's currently oversold. Some analysts are setting high price targets.

Bed Bath & Beyond, Inc. engages in the provision of an e-commerce platform. It offers furniture and home furnishing products and services. The company was founded on May 5, 1997 and is headquartered in Murray, UT.

Bed Bath & Beyond Inc.

Bed Bath & Beyond Inc

Bed Bath & Beyond ($BBBY) is trending amid discussions about its new corporate name and ticker symbol after Overstock acquired the rights, sparking confusion among investors. The community is buzzing about the potential of Tzero, a blockchain platform associated with the company, and its possible impact on preventing naked shorting, drawing comparisons to the $GME saga. Some traders are expressing skepticism while others speculate on Ryan Cohen's next move and the potential for new stores.

Kenvue, Inc. is a consumer health company, which engages in manufacturing and selling healthcare products which includes cosmetics, drugs, and medical devices. Its brands include Aveeno, BAND-AID Brand, Johnson’s, Listerine, Neutrogena, and Tylenol. It operates through the following segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment includes cough, cold and allergy, pain care, digestive health, and smoking cessation. The Skin Health and Beauty segment offers face and body care, and others. The Essential Health segment focuses on oral care, baby care, women's health, and wound care. The company was founded on February 23, 2022 and is headquartered in Summit, NJ.

Kenvue Inc

Kenvue ($KVUE) is trending as the FDA considers the ineffectiveness of phenylephrine, an ingredient in popular decongestants like Sudafed PE, potentially impacting sales. Despite this, some analysts remain bullish, citing attractive entry points and a recent addition to the S&P 500, with the community actively monitoring price movements for potential buying opportunities.

Lucid Group, Inc. manufactures electric vehicles. It designs, develops, and builds energy storage systems for electric vehicles and supplies automakers with the battery pack system needed to power hybrid, plug-in, and electric vehicles. The company was founded in December 2007 and is headquartered in Newark, CA.

Lucid Group Inc

Lucid Group is trending amid mixed sentiments following its reverse stock split, with community discussions focusing on whether the company can avoid further dilution. Some investors express optimism, citing potential for a short squeeze and the closing of the Uber investment, while others remain bearish due to the company's cash burn and lowered price targets. The stock's performance is also being viewed in the context of the broader EV sector and comparisons to other companies in the space.

Snap, Inc. operates as a technology company, which engages in the provision of a visual messaging application that was created to help people communicate through short videos and images. The company was founded by Frank Reginald Brown IV, Evan Thomas Spiegel, and Robert C. Murphy in 2010 and is headquartered in Santa Monica, CA.

Snap Inc - Ordinary Shares - Class A

Snap Inc

$SNAP is trending as traders discuss potential catalysts including AI integration, a possible buyout, and speculation around increased interest from Reddit's WallStreetBets community. Community members are actively debating price targets, potential acquirers, and the impact of AI on the platform's future, while also noting the stock's high short interest and recent trading volume.

Innodata, Inc. is a data engineering company, which engages in providing artificial intelligence software platforms and management of its services. It operates through the following business segments: Digital Data Solutions (DDS), Synodex, and Agility. The DDS segment combines deep neural networks and human expertise in multiple domains to make unstructured information useable. The Synodex segment enables clients in the insurance and healthcare sectors to transform medical records into useable digital data and to apply technologies to the digital data to augment decision support. The Agility segment provides tools and related professional services that enable public relations and communications professionals to discover influencers, amplify messages, monitor coverage, and measure the impact of campaigns. The company was founded by Todd H. Solomon in 1988 and is headquartered in Ridgefield Park, NJ.

Innodata Inc

Innodata is trending due to community discussion around its recent earnings beat and future prospects in the AI sector, with some speculating on potential acquisitions or major contract wins. Bullish sentiment is fueled by institutional investment and the company's upcoming AI summit, though technical analysis suggests caution in the short term. Community members are actively debating its valuation and potential for growth, with some comparing it to competitors.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

IOVA Stock Drops 6% on $350M Common Stock Offering

Iovance shares slid 6% after unveiling a $350 million stock offering, raising dilution concerns while funding growth plans for Amtagvi and its pipeline. 

Shares of Iovance Biotherapeutics Inc. (IOVA) traded 4% higher on Tuesday morning after Health Canada approved the company’s immunotherapy for the treatment of advanced melanoma.On Stocktwits, retail sentiment around IOVA rose from ‘bearish’ to ‘neutral’ territory over the past 24 hours while message volume remained at ‘low’ levels. According to Stocktwits data, retail chatter around <a href="https://stocktwits.com/symbol/IOVA">IOVA</a> jumped 782% over the past 24 hours as of Tuesday's early hours and by 87% over the past seven days.<figure class="image"><img style="aspect-ratio:626/61;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_19_at_11_53_05_AM_png_6c5efda32c.webp" alt="IOVA's Sentiment Meter and Message Volume as of 11:50 a.m. ET on Aug. 19, 2025 | Source: Stocktwits" width="626" height="61"><figcaption>IOVA's Sentiment Meter and Message Volume as of 11:50 a.m. ET on Aug. 19, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user opined that the stock would have risen further had it not been for an overall market downturn and said that ‘patience will pay off.’<stembedurl>https://stocktwits.com/katanare/message/625784957</stembedurl>Iovance’s Amtagvi is a T-cell immunotherapy for the treatment of adult patients with unresectable or metastatic melanoma that has progressed on or after at least one prior systemic therapy and who have no satisfactory alternative treatment options. Advanced melanoma, also known as metastatic melanoma, refers to melanoma that has spread from the original site to other parts of the body.The marketing authorization in Canada was <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.iovance.com/news-releases/news-release-details/iovances-amtagvir-lifileucel-receives-health-canada-approval">granted</a> based on the safety and efficacy results from a mid-stage trial. The approval is conditional, pending results of trials to confirm its clinical benefit. However, for Iovance, the approval marks its first outside the U.S. “We expect to authorize our first Canadian treatment center within the next few months, and we continue to advance our ex-U.S. strategy for Amtagvi in additional markets,” said CEO Frederick Vogt.Iovance is also investigating Amtagvi in frontline advanced melanoma in a late-stage trial, as well as in additional solid tumor types. IOVA stock is down by 65% this year and by about 77% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/william-blair-highlights-tesla-robotaxi-upsides-versus-uber-waymo/chsgZU4RdgC">William Blair Highlights Tesla Robotaxi’s Upsides Versus Uber, Waymo: Find Out More</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Iovance Biotherapeutics company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Iovance Stock Rises 4% On Health Canada Approval For Cancer Immunotherapy: Retail Thinks ‘Patience Will Pay Off’

The approval from Health Canada is conditional, pending results of trials to confirm the immunotherapy’s clinical benefit.

Equity

IOVA Q2 Earnings Miss, Stock Down on EMA Filing Withdrawal for Amtagvi

Iovance shares plunge after Q2 miss and voluntary withdrawal of Amtagvi's EU filing, despite strong U.S. sales growth for the therapy.

Iovance Biotherapeutics (IOVA) Reports Q2 Loss, Lags Revenue Estimates

Iovance Biotherapeutics (IOVA) delivered earnings and revenue surprises of -13.79% and -9.64%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

MaxCyte, Inc. (MXCT) Reports Q2 Loss, Misses Revenue Estimates

MaxCyte (MXCT) delivered earnings and revenue surprises of -20.00% and -14.93%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Halozyme Therapeutics (HALO) Q2 Earnings and Revenues Surpass Estimates

Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of +25.20% and +13.84%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Shares of Iovance Biotherapeutics have dropped over 17% so far this week, on course to mark their worst weekly decline since mid-November 2024.&nbsp;The selloff aligns with broader pressure on small-cap stocks within the Russell 2000 index, which is sliding into correction territory as fears over prolonged higher interest rates grip the market.Macroeconomic concerns have intensified following robust U.S. jobs data, showing accelerating job growth and a lower unemployment rate of 4.1% in December.&nbsp;Small and mid-cap companies, like Iovance, are particularly sensitive to rate dynamics due to their reliance on borrowing compared to larger companies.<figure class="image"><img style="aspect-ratio:1314/1036;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/IOVA_poll_sentiment_and_message_volume_Jan_10_95fa61f76a.png" alt="IOVA poll sentiment and message volume Jan 10.png" width="1314" height="1036"><figcaption>IOVA poll sentiment and message volume Jan 10 as of 2 pm ET | source: Stocktwits</figcaption></figure>Despite the macro-driven plunge, sentiment for Iovance has turned ‘extremely bullish’ on Stocktwits, with the stock becoming one of the platform’s top three trending tickers on Friday afternoon.&nbsp;Many retail investors see the selloff as overdone, drawing attention to the company’s promising medical pipeline and proprietary technology.<stembedurl>https://stocktwits.com/thebullofwallst/message/599572619</stembedurl><stembedurl>https://stocktwits.com/parsnips/message/599576937</stembedurl>Some also speculated on the possibility of acquisition interest, citing Vertex Pharmaceuticals’ $4.9 billion premium buyout of Alpine Immune Sciences in 2024 as a precedent.&nbsp;<stembedurl>https://stocktwits.com/AngusMacbeth/message/599584221</stembedurl>In November, Iovance CEO Frederick Vogt highlighted the strong U.S. launch of Amtagvi for advanced melanoma and its growing demand through an expanding network of authorized treatment centers. "As a fully integrated company, Iovance is well positioned to remain the global leader in innovating, developing, and delivering current and future generations of TIL cell therapy for patients with cancer," he added.Tumor-infiltrating lymphocyte (TIL) therapy is an innovative, patient-specific approach that uses T-lymphocytes derived from a patient’s tumor to combat cancer cells.Retail optimism about TIL therapy remains high, with 67% of respondents in a Stocktwits poll calling it a “game-changer” in cancer treatment.&nbsp;The therapy this week gained visibility as MedStar Georgetown University Hospital became the first in the Washington, D.C., area to offer it for metastatic melanoma.Iovance’s retail following has grown by 65% over the past year, even as the stock has shed more than 30% during the same period.The company’s stock remains a battleground for investors, with short interest hovering at 19.5%.&nbsp;While macroeconomic challenges weigh on small caps, retail investors remain steadfast in their optimism, betting on TIL therapy’s transformative potential to reshape cancer treatment.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Illustration depicting tumour infiltrating lymphocyte (TIL) therapy for cancer treatment. During TIL therapy, T-cells (blue) that recognise tumour cells (red) are obtained from a patient. | Image source: Getty Images

Cancer Drug Maker Iovance Tumbles Toward Worst Week Since November, But Retail Feels Macro Selloff Overblown

In November, Iovance CEO Frederick Vogt highlighted the strong U.S. launch of Amtagvi for advanced melanoma and its growing demand through an expanding network of authorized treatment centers.

Iovance Stock Tumbles On Macro Concerns, But Retail Stays Bullish On TIL Cancer Therapy Potential

This Penny Stock Has 270% Upside Potential in 2025. Is It a Buy Now?

Shares of this biotech company have had a rough ride in 2024, but analysts are feeling good about its future.

Biotech Companies' Q3 Updates: Promising Cancer Treatments on the Horizon

Biotech Companies' Q3 Updates: Promising Cancer Treatments on the Horizon Biotech Companies' Q3 Updates: Promising Cancer Treatments on the Horizon PR Newswire VANCOUVER, BC, Nov. 14, 2024 USA News...

A Peek at Iovance Biotherapeutics's Future Earnings

Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

IOVA
Iovance Biotherapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest IOVA News

IOVA Iovance Biotherapeutics Inc